GENOMEFRONTIER

Using the Quantum Engine™, GenomeFrontier is developing multiple cell modified gene therapy products, including chimeric antigen receptor T (CAR-T) and T cell receptor T (TCR-T) therapies. These are live, cell-based "drugs" composed of immune cells that have been genetically engineered to greatly enhance targeting and/or fighting capabilities against cancer... G enomeFrontier is an innovation-driven therapeutic company, focusing on the development of next-generation gene therapies. Striving to reach the pinnacle in the field of gene therapy, we leveraged four proprietary virus-free gene and cell engineering platforms and successfully created a robust cell-engineering Quantum Engine™ system that can potentially cure a wide range of diseases, including cancer... Our mission is to develop innovative gene therapies and cell therapies that are affordable and therapeutically effective.

Also known as: GenomeFrontier Therapeutics TW, GenomeFrontier Therapeutics TW Co., Ltd., GenomeFrontier Therapeutics, Inc.